chymotrypsin like elastase 2AGenealiases: AOMS4 · ELA2A · PE-1
Q-omics provides the consensus-scored CELA2A profile across patient tissues and cancer cell-line models. CELA2A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CELA2A is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, CELA2A RNA expression shows 11,717 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where CELA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CELA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CELA2A survival associations across molecular data types. CELA2A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CELA2A RNA expression–survival associations across cancer types. High CELA2A expression shows unfavorable associations in KIRC, CESC and THYM, but favorable associations in HNSC, MESO and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CELA2A RNA expression.
This table summarizes CELA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CELA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CELA2A shows lower tumor expression in KICH and LUAD and higher tumor expression in LIHC, BRCA, HNSC and CHOL. The KICH box plot shows higher CELA2A RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p = .002).
This table shows molecular features associated with CELA2A in patient tissues and cancer cell lines. In patient samples, CELA2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CELA2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
